David Risinger

Merck & Co., Inc. (NYSE: MRK)’s Keytruda returned better-than-expected results in the Keynote-189 lung study — a feat seen to lend a competitive edge over Bristol-Myers Squibb Co (NYSE: BMY). The Rating Morgan Stanley analyst David Risinger upgraded Merck from Equal-weight to...

Zoetis Inc (NYSE: ZTS) rose 56 percent over the past 12 months to come within striking distance of Morgan Stanley’s price target, closing the upside gap and and triggering a downgrade from the sell-side firm.  The Rating Analyst David Risinger downgraded Zoetis to Equal Weight and...

Morgan Stanley named three reasons for its positive opinion on Irish pharma company Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) in a Monday report.  The Analyst Analyst David Risinger upgraded shares of Jazz Pharma from Equal-weight from Overweight and increased the price target from $167 to $...

After two years on the sidelines, Morgan Stanley is taking a more bullish bet on Mylan NV (NASDAQ: MYL). A Tuesday upgrade boosted Mylan's ratings ratio to 13 Buys and seven Holds. The Rating Analyst David Risinger raised Mylan from Equal-weight to Overweight and increased the price target...

Bristol-Myers Squibb Co (NYSE: BMY) stock is up 26.5 percent year-over-year, making a partial recovery from a mid-2016 plunge, and one analyst anticipates upside worthy of a new all-time high. The Rating Morgan Stanley analyst David Risinger upgraded Bristol-Myers from Equal-Weight to Overweight...

Zoetis Inc (NYSE: ZTS), a global leader in animal health products, continues to benefit from favorable industry trends — which is attracting the attention of investors and Wall Street analysts. The Analyst Morgan Stanley's David Risinger upgraded Zoetis' stock rating from Equal-...

Allergan plc Ordinary Shares (NYSE: AGN) have seen heavy selling pressure throughout parts of 2017, but some analysts are encouraging investors to take advantage of the weakness. The Analyst Morgan Stanley's David Risinger upgraded Allergan's stock rating from Equal-weight to Overweight...

The bullish case for Merck & Co., Inc. (NYSE: MRK) has been "derailed" after the company signaled to investors last week a longer-than-expected delay in a key lung cancer trial for its Keytruda therapy. Morgan Stanley's David Risinger downgrades Merck's stock rating from Overweight to Equal-...

Analysts at Morgan Stanley turned bullish on Pfizer Inc. (NYSE: PFE) amid multiple catalysts and accretive M&A opportunities ahead. Analyst David Risinger upgraded Pfizer's stock from Equal-weight to Overweight with a price target boosted from $35 to $39. Ibrance Pfizer's pipeline is...

Morgan Stanley reduced its price target on the shares of Mylan N.V. (NASDAQ: MYL) following downward revision to its estimates due to the IMS trends, generic price pressure and uncertain new launch timing. Meanwhile, in a separate note, Mylan announced its NDA for TLD, a combo of Lamivudhine...

After a disastrous week last week for Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) shareholders, this week is off to a bumpy start as well. Just days after Teva reported a second-quarter earnings miss, lowered guidance and slashed dividend by 75 percent, Morgan Stanley stepped in and...

Merck & Co., Inc. (NYSE: MRK) unexpectedly announced a priority review for Keytruda plus chemo in first-line lung cancer. This, along with the previous announcements related to Keytruda, extends the company’s leadership position in immuno-oncology, Morgan Stanley’s David Risinger...

Morgan Stanley has slashed its price target on Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares by $17 to $25, saying it underestimated generic pressures on the company's older franchises and the risk of an ex-U.S. franchise slowdown. The latest action follows Valeant’s poor third-...